You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

The State of Therapeutics in Colorectal Cancer: Where Are We Heading?

  • Authors: Ian Chau, MD, PhD; Christina Wu, MD; John Strickler, MD
  • CME / ABIM MOC Released: 7/22/2022
  • Valid for credit through: 7/22/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, gastroenterologists, surgeons, and other healthcare providers (HCPs) who care for patients with colorectal cancer (CRC).

The goal of this activity is that learners will be better able to increase oncologists’ and other clinicians’ knowledge of the latest clinical data presented at the 2022 European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer regarding the management of CRC and to provide recommendations for integrating the data into clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Key clinical trial data for the treatment of CRC reported at the 2022 ESMO World Congress on Gastrointestinal Cancer
    • Subgroups of patients with CRC who benefit from emerging therapies
  • Demonstrate greater confidence in their ability to
    • Stay abreast of evolving areas of interest for therapies in CRC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Ian Chau, MD, PhD

    Professor of Medical Oncology
    Royal Marsden Hospital
    London & Surrey, United Kingdom

    Disclosures

    Ian Chau, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Astellas; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim; Bristol Meyers Squibb; Daiichi Sankyo, Inc.; Eisai, Inc.; Eli Lilly and Company; GlaxoSmithKline; Incyte; Merck-Serono; Merck Sharp & Dohme; OncXerna; Roche; Seagen Inc., formerly Seattle Genetics, Inc.; Servier; Sotio; Taiho; Turning Point
    Speaker or member of speakers bureau for: Eli Lilly and Company; Eisai, Inc.; Servier
    Research funding from: Eli Lilly and Company; Janssen-Cilag

  • Christina S. Wu, MD

    GI Medical Oncologist
    Senior Associate Consultant
    Mayo Clinic
    Scottsdale, Arizona, United States

    Disclosures

    Christina S. Wu, MD, has the following relevant financial relationships:
    Consultant or advisor for: Daiichi Sankyo, Inc.; Pfizer Inc.
    Research funding from: Boston Biomedical Inc; Inhbrx; Lycera; Pfizer Inc.; Rapt Therapeutics; Seagen Inc., formerly Seattle Genetics, Inc.; Symphogen A/S; Vaccinex

  • John Strickler, MD

    Associate Professor of Medicine
    Duke University Medical Center
    Durham, North Carolina, United States

    Disclosures

    John Strickler, MD, has the following relevant financial relationships:
    Consultant or advisor for: Abbvie; AstraZeneca; Bayer; GlaxoSmithKline; Inivata; Mereo Biopharma; Natera; Pfizer Inc.; Pionyr Immunotherapeutics; Seagen Inc., formerly Seattle Genetics, Inc.; Silverback Therapeutics; Takeda; Viatris
    Research funding from: Abbvie; Amgen; AStar D3; Bayer; Curegenix; Daiichi Sankyo, Inc.; Erasca; Gossamer Bio; Nektar; Roche/Genentech; Sanofi; Seagen Inc., formerly Seattle Genetics, Inc.; Silverback Therapeutics

Editors

  • Davecia Ragoonath-Cameron, MS

    Medical Education Director, Medscape, LLC

    Disclosures

    Davecia Ragoonath-Cameron, MS, has no relevant financial relationships.

  • Charlotte Warren

    Senior Director, Content Development, Medscape, LLC

    Disclosures

    Charlotte Warren has no relevant financial relationships.

Compliance Reviewer

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer:

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

The State of Therapeutics in Colorectal Cancer: Where Are We Heading?

Authors: Ian Chau, MD, PhD; Christina Wu, MD; John Strickler, MDFaculty and Disclosures

CME / ABIM MOC Released: 7/22/2022

Valid for credit through: 7/22/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Anti-HER2 Therapies in CRC

Are you up to date on the latest data coming out of ESMO 2022 for colorectal cancer?
Ian Chau, MD, PhD

Updated on Targeted Therapies in CRC

Are you up to date on the latest data related to targeted therapies for CRC?
John Strickler, MD

Advances in Immunotherapy for CRC

Get the latest updates on immunotherapy for CRC from ESMO 2022.
Christina Wu, MD
 

Assessment Survey

The goal of this activity is that learners will be better able to increase oncologists’ and other clinicians’ knowledge of the latest clinical data presented at the 2022 European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer regarding the management of CRC and to provide recommendations for integrating the data into clinical practice

Before you begin, please take this brief survey.

  • Print